Abstract
Long-acting injectable antipsychotic (LAIA) drugs are approved by the European Medication Agency for the treatment of schizophrenia in adults. Nevertheless, clinicians everywhere have been gathering experiences on the off-label use of these medications in children, adolescents, and young adults and in different disorders. The main aim was to analyze the indications and patterns of prescription of LAIA drugs in children, adolescents, and young adults from a naturalistic clinical sample group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
